The Fentanyl HCl Patient-Controlled Transdermal System (PCTS)

摘要: Inadequate pain control in the postoperative period not only contributes to patient discomfort, but also causes physiological changes that may result increased risk of myocardial ischaemia, deep vein thrombosis and pulmonary embolism. These events complicate recovery lead longer hospital stays as well healthcare costs. Patient-controlled analgesia (PCA) has emerged an effective way for patients manage their pain, allowing self-administration small doses analgesics maintain a certain level control. PCA is most commonly delivered via intravenous (IV) or epidural route, while satisfaction higher with than conventional methods analgesic administration, invasiveness, costs errors associated currently available modalities limit utility. systems require significant resources, nurses must manually program pumps deliver correct amount medication. Several new are being developed address these limitations. drug through variety routes, including nasal transmucosal transdermal. Most notably, self-contained, credit card-sized, transdermal system final stages development. The fentanyl HCl patient-controlled (PCTS; IONSYS™, Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ) uses imperceptible, low-intensity direct current transfer on demand across skin into systemic circulation. This compact patient-activated, can be applied patient’s upper arm chest, designed moderate-to-severe requiring opioid analgesia. delivers preprogrammed over 10 minutes, total 80 doses, 24 hours, whichever occurs first. on-demand dosing pharmacokinetics this differentiate it from passive formulation management chronic pain. Clinical studies have shown PCTS acute demonstrated safe tolerated by patients.